Navigation Links
Transgene: Cash Position of EUR 119 Million as of September 30, 2007
Date:10/10/2007

STRASBOURG, France, October 10 /PRNewswire-FirstCall/ -- Transgene S.A. (Eurolist Paris: FR0005175080) announces that cash, cash equivalents and short term investments totaled EUR 119 million at September 30, 2007 compared to EUR 114.3 million at June 30, 2007 (unaudited figures, IAS/IFRS).

For the first nine months of 2007, cash, cash equivalents and short term investments increased by EUR 98.7 million. This was mainly due to payments received from the partnership agreement with Roche (EUR 23 million), the capital increase carried out in June and July 2007 (net proceeds: EUR 95.3 million) and cash expenditures of EUR 19.6 million.

About Transgene:

Transgene is a France-based biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. The company has one product which has completed Phase II trials (TG4001/R3484), two compounds in Phase II trials (TG4010 and TG1042) and one compound in Phase I studies (TG4040). Transgene has concluded a strategic partnership agreement with Roche for the development of its TG4001/R3484 therapeutic vaccine to treat HPV-mediated diseases. Transgene has bio-manufacturing capacities for viral-based vectors and technologies available for out-licensing. Additional information about Transgene is available on the Internet at http://www.transgene.fr.


'/>"/>
SOURCE Transgene S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
2. Wisconsin early-stage companies must position themselves to get capital
3. New UW position focusing on Internet security
4. Midwest holds strong position in worldwide diagnostics business
5. Doyle praises Frists new stem cell research position
6. GE promotes Milwaukee-area CEO to London position
7. Is IT leadership a position or an attitude?
8. nPoint announces new nanopositioning scanning control mode
9. Venture Investors early-stage fund grows to $115 million
10. Two convicted of selling $6 million in counterfeit Rockwell software on eBay
11. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... 2017 , ... RoviSys, a leading independent provider of comprehensive ... an office in Taipei, Taiwan. This new location allows RoviSys to better support ... in the region. Located in the Neihu area of Taipei, the office allows ...
(Date:9/19/2017)... ... 19, 2017 , ... The new and improved Oakton® pocket testers, from Cole-Parmer, ... upright with a new cap design that is versatile, functional and leakproof. They are ... to test water quality. , The Oakton pocket testers have many user-friendly and functional ...
(Date:9/19/2017)... (PRWEB) , ... September 19, ... ... York State Department of Financial Services (NYS DFS) cybersecurity regulations have ... banking, finance and insurance organizations operating in the state (“Covered Entities”) to ...
(Date:9/18/2017)... ... September 18, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, announces Bryan ... conference. , What: Digital Transformation in Medical Device – The Journey to FDA ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):